Only Days After Hinting at an IPO, PureTech Acquires Lymphedema Asset

Only days after announcing it was considering an initial public offering (IPO) on the Nasdaq, PureTech Health, based in Boston and listed in the UK, reported it had acquired a small molecule candidate from an unidentified biopharma company. No financial details were disclosed.